high triglycerides and glp-1 The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GLP-1-based therapies for type 2

Obesity itself is one of the most underrecognized causes of low milk supply, working through several mechanisms: excess fat tissue slows the hormonal shift that "turns on" full milk production after delivery, high leptin levels interfere with prolactin response, and insulin resistance (extremely common in obesity) disrupts the metabolic signaling your mammary gland needs to produce milk efficiently

Mexico offers a comprehensive selection of premium GLP-1 therapies containing highly effective active ingredients like Semaglutide or Tirzepatide

Both improve insulin sensitivity through different mechanisms

Nat Med (2018) 24:152631